Pharmacist Medication Insights: Parathyroid Hormone (Natpara) for Hypocalcemia

Parathyroid hormone (Natpara) is indicated to control hypocalcemia in patients with hypoparathyroidism.

Shire’s parathyroid hormone (Natpara) is indicated to control hypocalcemia in patients with hypoparathyroidism.

The FDA approved Natpara in January 2015 as an adjunct to calcium and vitamin D therapy. The bioengineered replica of human parathyroid hormone is self-administered once a day by subcutaneous injection, and it is available in 4 dosage strengths: 25 mcg, 50 mcg, 75 mcg, and 100 mcg.

The most common side effects associated with Natpara include a tingling, tickling, or burning feeling on the skin, as well as headache and nausea.

Related Videos
Burnout illustration | Image credit: Vikky Mir - stock.adobe.com
Public Health Matters podcast logo
Smiling Asian female pharmacist working in chemist shop or pharmacy | Image Credit: Atstock Productions - stock.adobe.com
sofiko14 / stock.adobe.com
WP_7824 / stock.adobe.com
Child being measured by physician | Image credit: Africa Studio - stock.adobe.com
Women applying weight loss medication | Image credit: Mauricio - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.